Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18261954 | GENE ACTIVATION TARGETS FOR ENHANCED HUMAN T CELL FUNCTION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18266093 | COMPOSITIONS AND METHODS FOR GENE EDITING WITH WOOLLY MAMMOTH ALLELES | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18725696 | USE OF IMMUNOSUPPRESSION TO ENABLE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17948382 | METHODS OF CONTROLLING ANTIBODY HETEROGENEITY | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17969979 | Methods for high throughput cryopreservation of cell clusters | Non-Final OA | Regents of the University of Minnesota |
| 18548751 | VECTOR, LINEAR COVALENTLY CLOSED DNA PRODUCTION METHOD USING VECTOR, PARVOVIRUS VECTOR PRODUCTION METHOD, AND PARVOVIRUS-VECTOR-PRODUCING CELL PRODUCTION METHOD | Non-Final OA | KANEKA CORPORATION |
| 18250996 | PSEUDOTYPED PARTICLES, MODIFIED CELLS, RELATED COMPOSITIONS, AND RELATED METHODS | Final Rejection | CHILDREN'S HOSPITAL MEDICAL CENTER |
| 17797633 | METHOD OF TREATING GENE THERAPY ASSOCIATED TOXICITY WITH ANTIBIOTICS | Non-Final OA | ASKBIO INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy